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Dysregulated signaling via the epidermal growth factor receptor (EGFR)-family is believed
to contribute to the progression of a diverse array of cancers. The most common variant of
EGFR is EGFRvIII, which results from a consistent and tumor-specific in-frame deletion of
exons 2–7 of the EGFR gene. This deletion generates a novel glycine at the junction and
leads to constitutive ligand-independent activity. This junction forms a novel shared tumor
neo-antigen with demonstrated immunogenicity in both mice and humans. A 21-amino acid
peptide spanning the junctional region was selected, and then one or five copies of this 21AA neo-peptide were incorporated into live-attenuated Listeria monocytogenes-based vaccine vector. These vaccine candidates demonstrated efficient secretion of the recombinant
protein and potent induction of EGFRvIII-specific CD8+ T cells, which prevented growth of
an EGFRvIII-expressing squamous cell carcinoma. These data demonstrate the potency of
a novel cancer-specific vaccine candidate that can elicit EGFRvIII-specific cellular immunity,
for the purpose of targeting EGFRvIII positive cancers that are resistant to conventional
therapies.

Introduction
The epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase critical for cell
growth and survival. Overexpression of EGFR is frequently associated with human cancers
including breast cancer, non-small cell lung cancer, ovarian cancer and malignant glioma [1–
3]. Approximately 40% of glioblastoma multiforme (GBM) patients have tumors that overexpress EGFR [2]. Of these cases, approximately 70% also express a mutant form of the EGFR
[4]. The most common of these mutations is EGFR variant III (EGFRvIII), resulting from a
deletion of 267 amino acids spanning exons 2–7 of the EGFR gene [5]. This alteration of the
ligand-binding domain of EGFR alters the ability of the receptor to bind to its canonical
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ligands and produces low-level constitutive signaling activity [6]. Unlike wild-type (wt) EGFR,
EGFRvIII can form both homodimers as well as heterodimers with wt-EGFR and Her2, thus,
EGFRvIII signals may differ from those elicited by wt-EGFR [4]. These atypical signaling pairs
could explain why tumors expressing EGFRvIII are unusually resistant to the effects of tyrosine
kinase inhibitors [7] and anti-EGFR antibodies such as cetuximab [8]. In addition to promoting proliferation, EGFRvIII expression up-regulates the anti-apoptotic molecule Bcl-xL and
has been shown to mediate resistance to chemotherapeutic agents such as paclitaxel and cisplatin [9]. The presence of EGFRvIII also facilitates the STAT3-dependent induction of HIF1α and promotes cell motility, invasion and metastasis [10]. Furthermore, expression of
EGFRvIII by a subset of cells within a solid tumor can promote survival of EGFRvIII-negative
cells via the IL-6/LIF/gp130-dependent induction of wt-EGFR [11]. These findings correlate
with clinical data demonstrating that EGFRvIII expression in the presence of EGFR amplification is an indicator of a poor survival prognosis in GBM [12], and that EGFRvIII expression
independently correlates with poor prognosis in patients with gross-total resection (>95%)
surviving �1 year [13]. Therefore, EGFRvIII-expressing cells have a selective survival advantage over those expressing only wt-EGFR, and this advantage may become more pronounced
after treatment.
Previous studies have shown that patients with EGFRvIII-expressing cancers have spontaneously developed humoral and cellular immune responses against EGFRvIII, suggesting that
EGFRvIII serves as an immunogenic neo-antigen [14]. A 13 amino acid peptide from the
unique splice junction of EGFRvIII (LEEKKGNYVVTDH), referred to as PEPvIII, has been
used to vaccinate humans with EGFRvIII-expressing GBM. A phase 2 clinical trial of rindopepimut, a peptide vaccine containing PEPvIII conjugated to the carrier protein keyhole limpet
hemocyanin (KLH), administered with adjuvant GM-CSF was performed in newly diagnosed
GBM patients treated by gross total resection, radiation and temozolomide who had no radiographic evidence of progression. Humoral immune responses to EGFRvIII were observed in 6
of 14 immunized patients, while 3 of 17 showed a positive delayed type hypersensitivity (DTH)
response. The median overall survival for patients treated with vaccine in combination with
temozolomide was 26.0 months from the time of histologic diagnosis, versus 15.0 months for a
matched cohort receiving only temozolomide [15]. However, a follow-up randomized, double-blind phase 3 trial of 745 patients (405 with minimal residual disease and 338 with significant residual disease, following maximal surgical resection and chemoradiation) treated with
rindopepimut and temozolomide found no significant difference between patients receiving
the investigational vaccine and patients treated with KLH and temozolomide. Intriguingly, in
the small number of post-treatment samples obtained, EGFRvIII was lost equivalently in both
the rindopepimut and control-treated patients [16]. Taken together, these results support the
utility of EGFRvIII as an immunotherapeutic target, but suggest a vaccine with improved
potency relative to PepvIII-KLH may achieve the desired outcome.
Intracellular microbes elicit a robust CD8+ T cell response in immunocompetent hosts, a
response necessary to kill infected cells and prevent microbial replication. With the goal of
eliciting a similar response, live attenuated versions of these intracellular microbes are being
explored as vectors for cancer vaccines. Listeria monocytogenes (Lm) is a ubiquitous Grampositive facultative intracellular bacterium typically found in soil and food that is nonpathogenic to immune competent individuals. A live-attenuated double deleted Listeria (LADD
Lm) vaccine platform has been developed and tested in several early-stage clinical trials [17,
18]. The LADD vaccine strain has complete deletions of two virulence genes: actA, required
for intracellular motility and cell-to-cell spread and internalin B (inlB), required for direct
hepatocyte invasion via the InlB-c-Met interaction [19]. The combination of the two deletions
in the LADD platform results in a 1000x attenuation compared to WT Lm and limits liver
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toxicity by eliminating direct hepatocyte invasion and ActA-mediated cell-to-cell spread into
hepatocytes from infected liver-resident Kupffer cells [20]. Importantly, the live-attenuated
vaccine vector elicits a potent innate and adaptive immune response. Vaccine-induced inflammation also promotes APC maturation, antigen processing and presentation, and T cell expansion, resulting in a robust antigen-specific CD8+ T cell response [21]. In combination with our
ability to construct Listeria that express tumor associated antigens, these inherent immunogenic properties make attenuated Listeria an attractive candidate for microbe-based cancer
vaccines. Here, we describe the design of an EGFRvIII-expressing LADD Lm strain and demonstrate its efficacy in a preclinical tumor model. We demonstrate that this vaccine yields
orders of magnitude higher EGFRvIII-specific CD8+ T cell responses compared to PepvIII-KLH in vivo, and effectively protects against EGFRvIII-expressing tumor challenge, indicating its potential for translation to treat EGFRvIII-expressing tumors in human trials.

Materials and methods
Antibodies, cells and reagents
Murine squamous cell carcinoma (SCCVII) cells [22] (generously provided by Walter T. Lee,
Duke Cancer Institute, Durham NC) were grown in 10% RPMI-1640 with L-glutamine (ThermoFisher Scientific, Waltham, MA) supplemented with 10% heat-inactivated FBS (Atlas
Biologicals, Fort Collins, CO), MEM Eagle Nonessential Amino Acid Solution, PenicillinStreptomycin, L-glutamine, HEPES Buffer (Lonza, Basel, Switzerland), and Sodium Pyruvate
Solution (ThermoFisher Scientific). Antibodies for flow cytometry include anti-mouse CD8αPerCP-Cy5.5 (clone 5H10, ThermoFisher Scientific), CD4-FITC (clone RM4-5, eBioscience,
San Diego, CA), CD154/CD40L-PE (clone MR1, eBioscience), anti-mouse IFNγ-APC (clone
XMG1.2, eBioscience) and TNF-PE-Cy7 (clone MP6-XT22, BD Biosciences, Franklin Lanes,
NJ). Peptides for restimulation were synthesized by A&A Labs (San Diego, CA). H-2Kk MHCtetramers incorporating the defined EEKKGNYV peptide (EGFRvIII murine epitope) were
obtained from the NIH Core Facility at Emory University, (Atlanta, GA).

Animal models
Female C57BL/6, BALB/c, SJL and C3H/HeJ mice aged 5–8 weeks were obtained from Jackson
Laboratories (Bar Harbor, ME) for use in these experiments. Animal protocols were approved
by Providence Health & Services IACUC (Animal Welfare Assurance No. A3913-01).

L. monocytogenes construction, growth and vaccination
All strains were based on the previously described parental LADD Lm (ΔactAΔinlB) strain
[17]. A 21-AA sequence (PASRALEEKKGNYVVTDHGSC) that overlaps the novel junction created by the 267-AA deletion in EGFRvIII was selected as the immunogenic peptide. Two
EGFRvIII20-40-expressing constructs were designed, one with a single copy of the peptide and
one with five copies. EGFRvIII20-40 was flanked by peptides predicted to facilitate cleavage
of the construct by the immunoproteasome. The fusion protein included a C-terminal
OVA257-264 (SIINFEKL) tag. The expression cassette was codon optimized for Lm and cloned
downstream of an actA promoter in-frame with the 100 N-terminal amino acids of the actA
gene. The expression cassette was cloned into a derivative of the pPL2 integration vector and
stably integrated at the tRNAArg locus of the bacterial chromosome of vaccine platform strain
as described previously [23]. To assess protein expression, vaccine strains were infected into
the mouse dendritic cell line DC2.4 and cell lysates were harvested for western blotting using
an antibody raised to the mature amino terminus of ActA as described [24]. To assess in vivo
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immunogenicity, BHI broth was inoculated with a single colony from a BHI agar plate and
grown overnight at 37˚C. Stationary phase cultures were split the next morning and allowed to
return to midlog phase before dilution and immunization. All doses were confirmed by plating
vaccination material. Lm-EGFRvIII or control Lm-Ova [25] were administered to mice at a
dose of 1x105-1x107 CFU retro-orbital IV, depending on mouse strain. For comparison,
groups of mice were vaccinated by subcutaneous injection of 50μg KLH-PEPvIII (generously
provided by Celldex Therapeutics) along with 2μg murine recombinant GM-CSF (R&D Systems, Minneapolis, MN).

Peptide stimulation, intracellular cytokine staining and flow cytometry
To enumerate EGFRvIII-specific T cells in following treatment, spleens were first dissociated
using a 70μm cell strainer (ThermoFisher Scientific) and syringe. Red blood cells were lysed
with ACK Lysing Buffer (Lonza) and the resultant splenocytes were washed three times in
PBS, counted and diluted to 1x106 viable cells/100μl. These cells were then stimulated with 1μg
peptide and 1μl GolgiPlug (Becton Dickinson) for four hours, washed 3X with PBS and surfaced stained with anti-mouse CD8α-PerCP-Cy5.5 and CD4-FITC. Following the protocol for
the BD Cytofix/Cytoperm Fixation/Permeabilization Solution Kit with GolgiPlug (Becton
Dickinson), cells were then fixed, permeabilized and frozen at -80˚C for future analysis. Upon
thawing, cells were washed and stained with anti-mouse IFNγ-APC, TNF-PE-Cy7, and CD40L
PE. Samples were analyzed using the BD LSRII flow cytometer (Becton Dickinson).

T2 peptide binding assay
Kk-expressing T2 cells (generously provided by Peter Cresswell, Yale University) are a Tapdeficient cell line that cannot assemble MHCI for presentation on the cell surface unless provided with exogenous MHC-binding peptides. The cells were incubated overnight with the
indicated concentrations of peptide. Cells were washed, stained with an anti-Kk antibody
(eBiosciences) and acquired using an LSR II flow cytometer.

Plasmids and transfection
MSCV-XZ066-EGFRvIII was a gift from Alonzo Ross [26] (Addgene plasmid #20737) and
pMSCV-loxp-dsRed-loxp-eGFP-Puro-WPRE was a gift from Hans Clevers [27] (Addgene
plasmid #32702). SCCVII cells were transfected using Lipofectamine 2000 Transfection
Reagent (Life Technologies, Carlsbad, CA, USA) according to the manufacturer protocol and
selected in 2μg/ml puromycin as well as through three cycles of fluorescence-assisted cell sorting (FACS) for high endogenous GFP and RFP expression, respectively, to generate
SCCVII-EGFRvIII and SCCVII-control cells, respectively.

In vivo tumor assays
For tumor protection studies, female C3H mice were vaccinated with 1x105 CFU of LmEGFRvIIIx5 or Lm-OVA at day -21 and again at day -7 relative to tumor challenge. At day 0,
animals were injected subcutaneously with 2x106 tumor cells (SCCVII-EGFRvIII or SCCVII-Vector) on the hind flank according to group. For dual flank experiments, female C3H mice
were given simultaneous challenge of SCCVII-EGFRvIII and SCCVII-Vector on opposing
hind flanks. Starting at day 7, tumor progression was monitored on both flanks with calipers
to the endpoint of 12mm maximum diameter for either tumor, at which point the animal was
euthanized. For long-term protection experiments, female C3H mice were vaccinated with
1x105 CFU of Lm-EGFRvIIIx5 or Lm-Ova at day -21 and again at day -7 relative to tumor
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challenge. At day 0, mice were injected subcutaneously with SCCVII-EGFRvIII or SCCVIIvector control on the hind flank according to group. For therapeutic studies, at d0 mice were
injected subcutaneously with SCCVII-EGFRvIII as above and treated with Lm-EGFRvIIIx5 or
vehicle control on d3. Tumor size was monitored from day 7 with calipers to the endpoint of
12mm maximum diameter, at which point the animal was euthanized.

Statistics
Data were analyzed and graphed using Prism (GraphPad Software, La Jolla, CA). Individual
data sets were compared using Student’s T-test and analysis across multiple groups was performed using ANOVA with individual groups assessed using Tukey’s comparison. Overall survival of groups was compared using log rank test for differences in Kaplan-Meier survival
curves.

Results
Construction of Lm-EGFRvIII
To generate an immunogenic EGFRvIII vaccine candidate, we cloned the EGFRvIII20-40 neoepitope formed as a result of deletion of a -267 amino acid section of EGFR, which results in a
novel glycine at the deletion junction (Fig 1A). A larger, -21 amino acid peptide was selected
(relative to the previously published 14-mer) to increase potential MHC class I binding epitopes. The initial EGFRvIII construct, EGFRvIII x1, contained a single copy of the EGFRvIII20-40 peptide flanked by peptides predicted to facilitate cleavage of the construct by the
immunoproteasome. To investigate whether we could increase immunogenicity without also
increasing pathogenicity, we developed an EGFRvIII x5 construct that contains five copies of
the EGFRvIII20-40 peptide. Vaccine constructs were stably integrated each at the tRNAArg locus
of the chromosome in the LADD Listeria strain (Fig 1B). Under control of the actA promoter,
expression and secretion of the EGFRvIII fusion proteins will be maximal following escape of
Listeria into the cytoplasm of the host cell. To assess the expression and secretion of full-length
antigen fusion proteins, we routinely include the model epitope SIINFEKL (OVA257-264, from
chicken ovalbumin) at the C-terminus. Additionally, the SIINFEKL-specific CD8+ T cell
response serves as a standard to compare secretion and immunogenicity of different constructs
in vivo. We first verified the secretion of the EGFRvIII constructs in vitro. To this end, we
infected DC2.4 cells with Lm-EGFRvIII x1, Lm-EGFRvIII x5 or controls and prepared cytoplasmic extracts 7 hours post infection. All of the EGFRvIII20-40 containing constructs were
detected indicating effective uptake and protein secretion in antigen presenting cells compared
to controls (Fig 1C).
A reliable metric of antigen secretion efficiency is to include the Kb-restricted SIINFEKL
peptide at the C-terminus of a construct, and then assess the magnitude of the SIINFEKL-specific CD8+ T cell response in vivo. C57BL/6 mice were immunized with 1x107 colony forming
units (CFU) of either Lm-EGFRvIII x1 or Lm-EGFRvIII x5, each containing a single copy of
the SIINFEKL peptide. Seven days later, spleens were harvested and the number and frequency
of SIINFEKL-specific CD8+ T cells was determined by IFN-γ intracellular staining (ICS) in
response to peptide stimulation. We found that following a single immunization approximately 20% of the CD8+ T cells in the spleen were SIINFEKL specific, and the SIINFEKL-specific responses elicited by the Lm-EGFRvIII x1 and Lm-EGFRvIII x5 strains were equivalent
(Fig 2). These data demonstrate that the construct promoted efficient and comparable secretion of the antigenic polypeptides from the bacteria into the infected cell cytoplasm, resulting
in robust antigen-specific CD8+ T cell responses following immunization.
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a) Cancer-specific EGFRvIII neoepitope
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b) Schematic of Lm-EGFRvIIIx1 and Lm-EGFRvIIIx5
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c) Fusion protein expression from infected DC2.4 cells

49382817Fig 1. Construction and confirmation of Lm-EGFRvIII. a) Deletion of a 267 amino acid section of EGFR results in
formation of EGFRvIII where amino acids from the amino terminus (blue) separated from the remainder of the EGFR
molecule (green) by a novel glycine (red) at the junction. The novel EGFRvIII20-40 sequence incorporates a
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characterized human HLA A0201 binding neoepitope. b) One or 5 copies of EGFRvIII20-40, together with a single copy
of the ovalbumin epitope SIINFEKL, were cloned in frame with the amino terminus of ActA and under control of the
actA promoter in the parental LADD Lm vector. c) DC2.4s were infected with Lm-EGFRvIII x1, Lm-EGFRvIII x5 or
controls and western blotted with antibodies specific for the mature amino terminus of the ActA fusion partner.
https://doi.org/10.1371/journal.pone.0209153.g001

Identification of a class I restricted EGFRvIII epitope
Thus far, murine class I-restricted epitopes in EGFRvIII have not been defined, which has limited the ability to comparatively evaluate vaccination approaches. In addition, using the precise
class I binding epitope improves responsiveness in restimulation assays (ICS or ELISpot) and
allows assembly of MHC-peptide tetramers. To identify murine class I-restricted epitopes in
EGFRvIII, as well as to perform a preliminary evaluation of immunogenicity, we immunized
C57BL/6 (H-2b), BALB/c (H-2d), C3H/HeJ (H-2k) and SJL (H-2s) mice with 1x107 CFU of
each EGFRvIII20-40 expressing strain and seven days later determined the frequency and specificity of EGFRvIII-specific CD8+ T cells in the spleen by IFN-γ ICS. Specificity of the response
was determined using an EGFRvIII20-40 overlapping peptide library comprised of 15-amino
acid peptides overlapping by 14 amino acids. We found that the greatest peptide-specific
CD8+ T cell response to EGFRvIII occurred in the C3H strain (H-2k) (Fig 3A). In order to
confirm and refine the exact amino acid sequence of the EGFRvIII class I-binding peptide, a
cohort of C3H mice were primed with 1x107 CFU Lm-EGFRvIII x5 and spleens were either
harvested seven days later or boosted 21 days later with 1x105 CFU Lm-EGFRvIII x5 and the
CD8+ T cell response was screened with the same peptide library. Additionally, we included
7-, 8- and 9-mer peptides refined from the 15-mer identified in the primary immunogenicity
assay. CD8+ T cells isolated from the spleens of primed and boosted mice responded to several
of the 15-amino acid peptides (Fig 3B). Using 7-, 8- and 9-mers from this sequence in the primary assay, we refined this peptide to identify the 8-amino acid peptide EEKKGNYV as a novel
class I restricted epitope (Fig 3B). The identified 8-mer, EEKKGNYV, was predicted to bind Kk
according to available prediction algorithms (SYFPEITHI). To confirm binding, we used a Kkexpressing T2 cell line, where peptide binding stabilizes the MHC class I molecule (in this case,
Kk) on the cell surface. When MHC Kk expression was evaluated with increasing concentrations of the peptide, EEKKGNYV (EGFRvIII26-33) was confirmed as the optimal binder of Kk
(Fig 3C). Finally, Kk-EGFRvIII26-33 tetramers were able to specifically identify T cells expanded
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Fig 2. In vivo vaccination with Lm-EGFRvIII results in antigen specific T cell responses. C57BL/6 mice were treated with Lm-EGFRvIII x1 and Lm-EGFRvIII
x5 and seven days later splenocytes were tested for their response to i) DMSO vehicle, or ii) SIINFEKL peptide by intracellular cytokine staining. iii) Percent of
CD3+CD8+ T cells and iv) absolute number of SIINFEKL-specific splenocytes. Each symbol represents one animal. NS = not significant. (Student’s T-test).
https://doi.org/10.1371/journal.pone.0209153.g002
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Fig 3. Identification of a novel murine class I epitope from EGFRvIII. a) BALB/c, C57BL/6, C3H and SJL mice were vaccinated with LmEGFRvIII and 7 days later tested by ICS for EGFRvIII-specific T cells using a library of overlapping peptides from EGFRvIII20-40, or a DMSO
vehicle control. Spleens from three mice per strain were used for restimulation. The percentage of IFN-γ+ events within the CD3+CD8+ T cell
gate are shown for each peptide; b) Splenocytes from C3H mice primed and boosted with Lm-EGFRvIII were stimulated using a library of
overlapping peptides from EGFRvIII20-40, or SIINFEKL as a negative control. A subgroup of peptides within the previously identified 15-mer
were used to define the optimal 9-mer peptide by ICS. c) H2Kk binding of EGFRvIII or control peptides was assessed by stabilization of surface
MHC I using flow cytometry. d) Identification of EGFRvIII-specific T cells in the spleen following prime-boost vaccination with Lm-EGFRvIII
using H2Kk-tetramers folded with the defined peptide EEKKGNYV.
https://doi.org/10.1371/journal.pone.0209153.g003

following vaccination of C3H mice with Lm-EGFRvIII (Fig 3D). These results define a novel
Kk-restricted epitope in EGFRvIII that can be used to assess the potency of EGFRvIII-containing vaccine candidates.

Immunogenicity of EGFRvIII-expressing vaccine candidates
A high frequency of tumor-specific MHC-peptide complexes on dendritic cells following vaccination is important for maximizing TCR signaling. This was the rationale for engineering
the Lm-EGFRvIIIx5 candidate, though it remained unclear if this would result in improved T
cell responses to a complex microbial-based vaccine. First, we compared the primary EGFRvIII-specific CD8+ T cell response after immunization with the EGFRvIII x1 or x5 strain.
Female C3H mice were immunized with 1x105 CFU of each strain, and seven days later spleens
were harvested and the frequency of EGFRvIII26-33–specific CD8+ T cells was determined by
ICS. Consistent with our hypothesis, the inclusion of multiple copies of EGFRvIII20-40 elicited
more EGFRvIII-specific CD8+ T cells than the EGFRvIII x1 single copy variant (Fig 4A).
Together with the data (Fig 2) showing equivalent transcription, translation and secretion of
the 1x and 5x polypeptides (both strains have only a single copy of SIINFEKL), these findings
demonstrate that increasing the frequency of class I-binding peptides directly impacts the
magnitude of the primary CD8+ T cell response.
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Fig 4. Immunogenicity of EGFRvIII vaccine candidates. a) EGFRvIII26-33 -specific CD8+ T cell responses in C3H mice vaccinated with Lm-EGFRvIIIx1 or LmEGFRvIIIx5, determined by IFN-γ ICS on day 7. b) Primary immunogenicity of PEPvIII and Lm-EGFRvIIIx5 in C3H mice, represented as the frequency of KkEGFRvIII26-33 -tetramer+ cells within the CD3+CD8+ T cell population. c) 21 days after immunization with Lm-EGFRvIIIx5 or a 3 dose regimen of PEPvIII, the
frequency of Kk-EGFRvIII26-33 -tetramer+ cells within the CD3+CD8+ T cell population was determined. d) C3H mice were vaccinated x3 with PEPvIII, or a single dose
of Lm-EGFRvIIIx5 as indicated. 21 days after the last vaccination, mice were boosted with PEPvIII or Lm-EGFRvIIIx5. Five days later, the frequency of Kk-EGFRvIII26-33
-tetramer+ cells within the CD3+CD8+ T cell population was determined. Each symbol represents one animal. Bars represent mean ± SEM of groups containing 4–5
animals. Each figure represents a single experiment from a minimum of two replicates. (ANOVA).
https://doi.org/10.1371/journal.pone.0209153.g004

PLOS ONE | https://doi.org/10.1371/journal.pone.0209153 January 2, 2019

9 / 16

EGFRvIII-expressing cancer vaccines

To compare the immunogenicity of the LADD Lm vaccine platform compared to the existing peptide vaccine, mice were vaccinated with Lm-EGFRvIII x5 or the EGFRvIII-specific
14-mer peptide coupled to keyhole limpet hemocyanin and co-administered with GM-CSF
(referred to as PEPvIII in subsequent text and figures) (Fig 4B–4D). First, we assessed T cell
responses 7 days after a single vaccination with Lm-EGFRvIIIx5 or PEPvIII, and found that
Lm-EGFRvIIIx5 consistently elicited 3–5 fold more EGFRvIII26-33 -specific CD8+ T cells than
PEPvIII (Fig 4B). Next, we compared a dosing regimen closer to what has been used in the
clinic with rindopepimut; i.e., multiple immunizations separated by 14 days. Mice were immunized with PEPvIII on days -28, -14, and 0, or with a single dose of Lm-EGFRvIIIx5 on day 0.
21 days later, the frequency of EGFRvIII26-33 -specific CD8+ T cells was determined using KkEEKKGNYV tetramers (Fig 4C). Consistent with the primary CD8+ T cell response, the frequency of EGFRvIII-specific CD8+ T cells was greater following Lm-EGFRvIIIx5 immunization than PEPvIII. On day 21, separate cohorts were boosted with either PEPvIII or LmEGFRvIIIx5 as either a homologous or heterologous prime-boost. Five days later, the frequency of EGFRvIII26-33 -specific CD8+ T cells in the spleen was determined. Mice boosted
with Lm-EGFRvIIIx5, whether they were primed with PEPvIII or Lm-EGFRvIIIx5, demonstrated robust secondary expansion (Fig 4D). Conversely, mice boosted with PEPvIII realized
comparatively modest secondary expansion. These findings are consistent with our understanding of inflammation as a driver of CD8+ T cell expansion. Together, these data demonstrate that a prime-boost of Lm-EGFRvIII x5 is significantly more effective at generating
EGFRvIII-specific CD8+ T cells than a prime-boost regimen of PEPvIII (Fig 4D). In addition,
Lm-EGFRvIII x5 is effective at boosting responses primed with PEPvIII, suggesting that it
could be applied in patients who have only weak responses to rindopepimut, to boost their
EGFRvIII-specific immunity. These data demonstrate that a multicopy EGFRvIII20-40-expressing LADD Lm-based vaccine readily promotes expansion of antigen-experienced CD8+ T cells
and can be repeatedly administered to generate long-term antigen-specific immunity.

Evaluation of Lm-EGFRvIII as an anti-cancer therapeutic
To test this agent as an anti-cancer therapeutic, we transfected the squamous cell carcinoma
cell line SCCVII that is syngeneic to C3H mice with an EGFRvIII plasmid construct (SCCVIIEGFRvIII) or the plasmid construct backbone alone (SCCVII-control) and generated stable
cell lines. C3H mice were primed with Lm-EGFRvIIIx5 or vehicle control and 14 days later
rechallenged with Lm-EGFRvIIIx5 or vehicle control. 7 days later mice were implanted with
SCCVII-EGFRvIII or with SCCVII-control (Fig 5AI). 7 days following tumor implantation,
mice were evaluated for EGFRvIII-specific T cell responses. CD8+ T cell responses to EGFRvIII were not detectable in unvaccinated mice and had declined in mice receiving no further
treatment or implanted with SCCVIII-control tumors (Fig 5AII). However, implantation of
SCCVII expressing EGFRvIII significantly boosted the EGFRvIII-specific CD8+ T cell
responses (Fig 5AII), indicating that the T cells generated by vaccination further expanded following recognition of antigens present in the cancer cells. To determine whether this resulted
in antigen-specific tumor control, C3H mice were primed with Lm-EGFRvIIIx5 or vehicle
control and 14 days later boosted with Lm-EGFRvIIIx5 or vehicle control. 7 days following the
boost vaccine mice were implanted with SCCVII-EGFRvIII on one flank and SCCVII-control
on the opposite flank (Fig 5BI). Mice given only vehicle developed tumors on both flanks,
while mice vaccinated with Lm-EGFRvIII only developed SCCVII-control tumors and failed
to develop EGFRvIII expressing SCCVII tumors (Fig 5BII). The progressive growth of the
antigen-negative tumor prevented long-term monitoring of these animals to evaluate late outgrowth of tumors due to loss of antigen-specific control. Therefore, we evaluated protection
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https://doi.org/10.1371/journal.pone.0209153.g005

against growth of a single tumor implanted in each animal. To evaluate long-term protection
against tumor outgrowth, C3H mice were primed with Lm-EGFRvIIIx5 or Lm-OVA as an
irrelevant antigen control, and 14 days later boosted with Lm-EGFRvIIIx5 or Lm-OVA. 7 days
following the boost vaccine mice were implanted with either SCCVII-EGFRvIII or SCCVIIcontrol. Mice vaccinated with Lm-EGFRvIIIx5 exhibited long term protection against growth
of tumors expressing EGFRvIII. These data demonstrate Lm-EGFRvIIIx5 is an effective vaccine that results in antigen-specific protection against EGFRvIII-expressing SCCVII tumors
(Fig 5C). To determine whether the vaccine was also effective in a therapeutic setting, mice
bearing SCCVII-EGFRvIII were left untreated or vaccinated with Lm-EGFRvIIIx5 and followed for outcome. Antigen-specific vaccination resulted in a significant extension in survival
(p<0.01) with 13/15 mice cured of their tumor across experimental repeats (Fig 5D). These
data demonstrate that in the preclinical setting, Lm-EGFRvIIIx5 is an effective anti-cancer
therapeutic for EGFRvIII-expressing tumors.
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Discussion
We demonstrate that potent EGFRvIII-specific CD8+ T cell responses can be elicited using
LADD, an attenuated L. monocytogenes strain, as the vaccine vector. Using this approach we
were able to define an EGFRvIII-specific CD8+ T cell epitope in C3H mice and demonstrate
control of EGFRvIII-expressing tumors in immunocompetent mice. LADD Lm-based vectors
are not susceptible to the same vector-specific neutralizing immunity that limits viral vaccine
vectors [28] and this represents a novel potent candidate vaccine for patients with EGFRvIIIexpressing tumors.
Previous reports using EGFRvIII-targeted vaccines have failed to demonstrate an EGFRvIII-specific T cell response in mice that could be measured by ICS or ELISpot [29–31]. When
compared with results from previous pre-clinical studies using recombinant protein or peptide-pulsed dendritic cells, we observe a significantly more potent in vivo T cell response to
our EGFRvIII-expressing vaccine. In addition to using a potent, live microbial vaccine vector,
we identified a novel Kk-restricted epitope, EEKKGNYV, within the EGFRvIII20-40 immunogen. Using this defined class I-restricted peptide, we were able to determine the magnitude
and quality of the EGFRvIII-specific CD8+ T cell response to Lm-EGFRvIII and the previously
described PepvIII-KLH conjugate. In addition, we were able to test the efficacy of the vaccine
candidate using a squamous cell carcinoma cell line, engineered to express full-length EGFRvIII, which was syngeneic to the C3H mouse strain and therefore able to present the EEKKGNYV peptide on H2k. This direct presentation was not possible on prior tumor models that
were tested in mice expressing MHC class I H2d haplotypes [29] or in human cells in immunosuppressed animals [30] and in these models tumor control was associated with antibody
rather than T cell responses [31].
Targeting T cell responses to EGFRvIII rather than antibody responses is particularly relevant in view the failure of the phase III PepvIII-KLH conjugate trial [16] and the promising
results of a recent phase 1 trial infusing EGFRvIII-specific chimeric antigen receptor (CAR) T
cells into recurrent glioblastoma patients. In this latter study, autologous T cells were engineered to express an EGFRvIII-binding CAR signaling through CD3z and the 4-1BB costimulation domain and then infused back into patients. These T cells were observed to effectively
traffic to tumors and significantly decreased EGFRvIII expression [32]. In patients, the PepvIII-KLH conjugate did generate a detectable antibody response to EGFRvIII, and the clinical
data suggested that antibody responses correlated with clinical activity [16]. We demonstrate
that PEPvIII does generate an antigen-specific T cell response to the neoantigen within EGFRvIII in C3H mice, and this vaccine had been shown to generate CD8 T cell-mediated tumor
control in murine models [31]. While one of the strengths of the Listeria platform is that
repeated vaccination is not limited by neutralizing antibody responses, antibody responses
may be elicited following Listeria infection and contribute to T cell immunity [33]. Further
studies are necessary to determine whether CAR T cell transfer or endogenous vaccination
yields superior results in clinical settings, and whether antibodies contribute to tumor control
by Lm-EGFRvIII.
EGFRvIII-expressing cancer cells frequently represent a subclonal population of the tumor,
and as discussed above, in the clinical studies tumor expression of EGFRvIII was lost equivalently in both the rindopepimut and control-treated patients [16]. While this suggests that the
cancer cells have a potential path to immune escape, the EGFRvIII+ cancer cells are more
resistant to chemotherapeutic agents such as paclitaxel and cisplatin [9] and a subclonal population of EGFRvIII+ cells can promote survival of EGFR wt neighbors [11]. Therefore, while
successful clearance of EGFRvIII+ cancer cells would not be expected to affect EGFR wt neighbors, it has the potential to render the tumor significantly more susceptible to conventional
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therapies as part of combination treatments. Moreover, a strong tumor-specific T cell response
has the potential to dramatically change the inflammatory environment of the tumor, and support epitope spreading to common mutations shared between EGFRvIII+ and EGFR wt neighbors. Thus the selectivity and specificity of the EGFRvIII epitope has the potential to
immunoedit the tumor to a more treatable state, and provide a focus for further immune control of residual disease.
Given our experience constructing and producing L. monocytogenes-based vaccines, data
with this vector in previous phase I clinical trials, and the demonstrated immunogenicity of
EGFRvIII20-40-expressing LADD Lm, we believe Lm-EGFRvIII to be an ideal candidate for
testing in patients with EGFRvIII-expressing cancers. The studies will include validation of the
EGFRvIII neo-eptiope as a target for CD8 T cells in patients. As such, a phase 1 study testing
ADU-623, a Listeria vaccine of similar construction expressing EGFRvIII-NY-ESO-1, is currently ongoing in patients with recurrent grade 3/4 glioblastomas (ClinicalTrials.gov identifier:
NCT01967758).
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